NVP-AEW541

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2016
01220042016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Triple-negative breast cancer (TNBC) is the most intractable type of breast cancer, and there is a lack of effective… (More)
Is this relevant?
2012
2012
Currently, there is no completely effective therapy available for metastatic phaeochromocytomas (PCCs) and paragangliomas. In… (More)
Is this relevant?
2010
2010
AIM To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF… (More)
Is this relevant?
2009
2009
Multiple myeloma is still incurable. Myeloma cells become resistant to common drugs and patients eventually die of tumour… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Multiple myeloma (MM) is a B-cell malignancy characterized by accumulation of monoclonal plasma cells in the bone marrow (BM… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Small-molecule insulin-like growth factor-I receptor (IGF-IR)-specific tyrosine kinase inhibitors have been recently… (More)
Is this relevant?
2006
2006
UNLABELLED Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death worldwide. Due to very poor 5… (More)
Is this relevant?
2006
2006
Purpose: Signaling through insulin-like growth factor I receptor (IGF-IR) is important for growth and survival of many tumor… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • table 2
Is this relevant?
2005
2005
Synovial sarcoma is a soft tissue malignancy with a poor prognosis; many patients will die from this disease within 10 years of… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
IGF-IR-mediated signaling promotes survival, anchorage-independent growth, and oncogenic transformation, as well as tumor growth… (More)
Is this relevant?